Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 26, 2017 - Issue 5
Submit an article Journal homepage
751
Views
41
CrossRef citations to date
0
Altmetric
Review

PPAR-α agonists are still on the rise: an update on clinical and experimental findings

Nicola FerriDipartimento di Scienze del Farmaco, Università degli Studi di Padova, Padua, ItalyCorrespondence[email protected]
View further author information
,
Alberto CorsiniDipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy;Multimedica IRCCS, Milano, ItalyView further author information
,
Cesare SirtoriCentro Dislipidemie, A.S.S.T. Grande Ospedale Metropolitano Niguarda, Milan, ItalyView further author information
&
Massimiliano RuscicaDipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, ItalyCorrespondence[email protected]
View further author information
Pages 593-602 | Received 05 Jan 2017, Accepted 24 Mar 2017, Published online: 11 Apr 2017

Citations (41)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

M. Ruscica, N. Ferri, C. Macchi, A. Corsini & C. R. Sirtori. (2018) Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. Annals of Medicine 50:6, pages 461-484.
Read now
Cesare R. Sirtori, Chiara Pavanello, Laura Calabresi & Massimiliano Ruscica. (2017) Nutraceutical approaches to metabolic syndrome. Annals of Medicine 49:8, pages 678-697.
Read now

Articles from other publishers (39)

Lijun Gong, Fang Wei, Frank J. Gonzalez & Guolin Li. (2023) Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines. Hepatology 78:5, pages 1625-1653.
Crossref
Mohammad Ali Karimi, Mehdi Goudarzi, Mohammad Javad Khodayar, Layasadat Khorsandi, Saeed Mehrzadi & Iman Fatemi. (2023) Gemfibrozil palliates adriamycin-induced testicular injury in male rats via modulating oxidative, endocrine and inflammatory changes in rats. Tissue and Cell 82, pages 102037.
Crossref
Yukino Katakura, Masashi Shimoda, Mana Ohnishi, Takashi Kusano, Kazunori Dan, Hayato Isobe, Ryo Wamata, Yuichiro Iwamoto, Yoshiro Fushimi, Junpei Sanada, Atsushi Obata, Tomohiko Kimura, Fuminori Tatsumi, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku & Hideaki Kaneto. (2023) Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study. Nutrition, Metabolism and Cardiovascular Diseases.
Crossref
Tingting Yan, Yuhong Luo, Nana Yan, Keisuke Hamada, Nan Zhao, Yangliu Xia, Ping Wang, Changdong Zhao, Dan Qi, Shoumei Yang, Lulu Sun, Jie Cai, Qiong Wang, Changtao Jiang, Oksana Gavrilova, Kristopher W. Krausz, Daxesh P. Patel, Xiaoting Yu, Xuan Wu, Haiping Hao, Weiwei Liu, Aijuan Qu & Frank J. Gonzalez. (2023) Intestinal peroxisome proliferator‐activated receptor α‐fatty acid‐binding protein 1 axis modulates nonalcoholic steatohepatitis. Hepatology 77:1, pages 239-255.
Crossref
Naofumi Amioka, Toru Miyoshi, Tomoko Yonezawa, Megumi Kondo, Satoshi Akagi, Masashi Yoshida, Yukihiro Saito, Kazufumi Nakamura & Hiroshi Ito. (2022) Pemafibrate Prevents Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms. Frontiers in Cardiovascular Medicine 9.
Crossref
Teruhiko Imamura, Nikhil Narang & Koichiro Kinugawa. (2022) Association between Pemafibrate Therapy and Triglyceride to HDL-Cholesterol Ratio. Journal of Clinical Medicine 11:10, pages 2820.
Crossref
Cesare R. Sirtori, Alberto Corsini & Massimiliano Ruscica. (2022) The Role of High-Density Lipoprotein Cholesterol in 2022. Current Atherosclerosis Reports 24:5, pages 365-377.
Crossref
Cutler T. Lewandowski, Megan S. Laham & Gregory R.J. Thatcher. (2022) Remembering your A, B, C's: Alzheimer's disease and ABCA1. Acta Pharmaceutica Sinica B 12:3, pages 995-1018.
Crossref
Lorenzo.G. de la Parra Soto, Janet A. Gutiérrez-Uribe, Ashutosh Sharma & Aurea K. Ramírez-Jiménez. (2022) Is Apo-CIII the new cardiovascular target? An analysis of its current clinical and dietetic therapies. Nutrition, Metabolism and Cardiovascular Diseases 32:2, pages 295-308.
Crossref
Claudia Manca, Stefano Pintus, Elisabetta Murru, Giovanni Fantola, Michela Vincis, Barbara Batetta, Enrico Moroni, Gianfranca Carta & Sebastiano Banni. (2021) Fatty Acid Metabolism and Derived-Mediators Distinctive of PPAR-α Activation in Obese Subjects Post Bariatric Surgery. Nutrients 13:12, pages 4340.
Crossref
Paola Dongiovanni, Erika Paolini, Alberto Corsini, Cesare R. Sirtori & Massimiliano Ruscica. (2021) Nonalcoholic fatty liver disease or metabolic dysfunction‐associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. European Journal of Clinical Investigation 51:7.
Crossref
Massimiliano Ruscica, Nicola Ferri, Raul D. Santos, Cesare R. Sirtori & Alberto Corsini. (2021) Lipid Lowering Drugs: Present Status and Future Developments. Current Atherosclerosis Reports 23:5.
Crossref
Cesare R Sirtori, Shizuya Yamashita, Maria Francesca Greco, Alberto Corsini, Gerald F Watts & Massimiliano Ruscica. (2019) Recent advances in synthetic pharmacotherapies for dyslipidaemias. European Journal of Preventive Cardiology 27:15, pages 1576-1596.
Crossref
Thakur Gurjeet Singh, Hardevinder Pal Singh, Sunpreet Kaur & Sonia Dhiman. (2020) Protective effects of sesamol against cisplatin-induced nephrotoxicity in rats: A mechanistic approach. Obesity Medicine 19, pages 100269.
Crossref
Jean-Charles Fruchart, Michel P. Hermans & Jamila Fruchart-Najib. (2020) Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?. Current Atherosclerosis Reports 22:8.
Crossref
Yujie Shi, Yixin Zou, Ziyue Shen, Yonghong Xiong, Wenxiang Zhang, Chang Liu & Siyu Chen. (2020) Trace Elements, PPARs, and Metabolic Syndrome. International Journal of Molecular Sciences 21:7, pages 2612.
Crossref
Massimiliano Ruscica, Francesca Zimetti, Maria Pia Adorni, Cesare R. Sirtori, Maria Giovanna Lupo & Nicola Ferri. (2020) Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia. Pharmacological Research 153, pages 104653.
Crossref
Michele Tufano & Graziano Pinna. (2020) Is There a Future for PPARs in the Treatment of Neuropsychiatric Disorders?. Molecules 25:5, pages 1062.
Crossref
Mariana Acuña‐Aravena & David E. Cohen. 2020. The Liver. The Liver 255 267 .
Haizhou Wang, Haiou Li, Yunjiao Zhou, Jing Liu, Fan Wang & Qiu Zhao. (2020) Pemafibrate Tends to have Better Efficacy in Treating Dyslipidemia than Fenofibrate. Current Pharmaceutical Design 25:44, pages 4725-4734.
Crossref
Sanne J. C. M. Frambach, Ria de Haas, Jan A. M. Smeitink, Gerard A. Rongen, Frans G. M. Russel & Tom J. J. Schirris. (2019) Brothers in Arms: ABCA1- and ABCG1-Mediated Cholesterol Efflux as Promising Targets in Cardiovascular Disease Treatment. Pharmacological Reviews 72:1, pages 152-190.
Crossref
Shizuya Yamashita, Daisaku Masuda & Yuji Matsuzawa. (2020) Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases. Current Atherosclerosis Reports 22:1.
Crossref
Montserrat Cofán & Emilio Ros. (2019) Use of Plant Sterol and Stanol Fortified Foods in Clinical Practice. Current Medicinal Chemistry 26:37, pages 6691-6703.
Crossref
Jean-Charles Fruchart & Raul D. Santos. (2019) SPPARM alpha. Current Opinion in Lipidology 30:6, pages 419-427.
Crossref
Massimiliano Ruscica, Marco Busnelli, Enrico Runfola, Alberto Corsini & Cesare R. Sirtori. (2019) Impact of PPAR-Alpha Polymorphisms—The Case of Metabolic Disorders and Atherosclerosis. International Journal of Molecular Sciences 20:18, pages 4378.
Crossref
Hui Yun Penny Oh, Vivegan Visvalingam & Walter Wahli. (2019) The PPAR–microbiota–metabolic organ trilogy to fine‐tune physiology. The FASEB Journal 33:9, pages 9706-9730.
Crossref
Henriette Arnesen, Nadia Nabil Haj-Yasein, Jørn E. Tungen, Helen Soedling, Jason Matthews, Steinar M. Paulsen, Hilde I. Nebb, Ingebrigt Sylte, Trond Vidar Hansen & Thomas Sæther. (2019) Molecular modelling, synthesis, and biological evaluations of a 3,5-disubstituted isoxazole fatty acid analogue as a PPARα-selective agonist. Bioorganic & Medicinal Chemistry 27:18, pages 4059-4068.
Crossref
C Macchi, M Banach, A Corsini, CR Sirtori, N Ferri & M Ruscica. (2019) Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents. European Journal of Preventive Cardiology 26:9, pages 930-949.
Crossref
Li Zhang, Weilei Yao, Jun Xia, Tongxin Wang & Feiruo Huang. (2019) Glucagon-Induced Acetylation of Energy-Sensing Factors in Control of Hepatic Metabolism. International Journal of Molecular Sciences 20:8, pages 1885.
Crossref
Pratik B Sandesara, Salim S Virani, Sergio Fazio & Michael D Shapiro. (2019) The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. Endocrine Reviews 40:2, pages 537-557.
Crossref
Shizuya Yamashita, Massimiliano Ruscica, Chiara Macchi, Alberto Corsini, Yuji Matsuzawa & Cesare R. Sirtori. (2018) Cholesteryl ester transfer protein: An enigmatic pharmacology – Antagonists and agonists. Atherosclerosis 278, pages 286-298.
Crossref
Stephen J. Nicholls, A. Michael Lincoff, Dianna Bash, Christie M. Ballantyne, Philip J. Barter, Michael H. Davidson, John J. P. Kastelein, Wolfgang Koenig, Darren K. McGuire, Dariush Mozaffarian, Terje R. Pedersen, Paul M. Ridker, Kausik Ray, Björn W. Karlson, Torbjörn Lundström, Kathy Wolski & Steven E. Nissen. (2018) Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clinical Cardiology 41:10, pages 1281-1288.
Crossref
James J. Connolly, Kohtaro Ooka & Joseph K. Lim. (2018) Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials. Journal of Clinical and Translational Hepatology 6:3, pages 1-12.
Crossref
Hidenori Arai, Shizuya Yamashita, Koutaro Yokote, Eiichi Araki, Hideki SuganamiShun Ishibashi. (2018) Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial. Journal of Atherosclerosis and Thrombosis 25:6, pages 521-538.
Crossref
Margherita Botta, Matteo Audano, Amirhossein Sahebkar, Cesare Sirtori, Nico Mitro & Massimiliano Ruscica. (2018) PPAR Agonists and Metabolic Syndrome: An Established Role?. International Journal of Molecular Sciences 19:4, pages 1197.
Crossref
Michael H Davidson. (2018) Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of LDL-C. European Heart Journal 39:7, pages 620-622.
Crossref
Jean-Charles Fruchart. (2017) Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovascular Diabetology 16:1.
Crossref
Kálmán Benke, Csaba Mátyás, Alex Ali Sayour, Attila Oláh, Balázs Tamás Németh, Mihály Ruppert, Gábor Szabó, Gábor Kökény, Eszter Mária Horváth, István Hartyánszky, Zoltán Szabolcs, Béla Merkely & Tamás Radovits. (2017) Pharmacological preconditioning with gemfibrozil preserves cardiac function after heart transplantation. Scientific Reports 7:1.
Crossref
Germán Camejo. (2017) Phase 2 clinical trials with K-877 (pemafibrate): A promising selective PPAR-α modulator for treatment of combined dyslipidemia. Atherosclerosis 261, pages 163-164.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.